Upozornenie: Prezeranie týchto stránok je určené len pre návštevníkov nad 18 rokov!
Zásady ochrany osobných údajov.
Používaním tohto webu súhlasíte s uchovávaním cookies, ktoré slúžia na poskytovanie služieb, nastavenie reklám a analýzu návštevnosti. OK, súhlasím









A | B | C | D | E | F | G | H | CH | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9

Pexelizumab
 
Pexelizumab
Monoclonal antibody
TypeSingle-chain variable fragment
SourceHumanized (from mouse)
TargetComplement component 5
Clinical data
ATC code
  • none
Legal status
Legal status
  • investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting[1] and angioplasty,[2][3] among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.[4]

Current status

Alexion, the developer of pexelizumab, stopped development when the phase 3 trial indicated the heart-attack drug is no better than placebo.[5]

References

  1. ^ Clinical trial number NCT00088179 for "Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass" at ClinicalTrials.gov
  2. ^ Clinical trial number NCT00091637 for "Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction" at ClinicalTrials.gov
  3. ^ Testa L, Van Gaal WJ, Bhindi R, Biondi-Zoccai GG, Abbate A, Agostoni P, et al. (October 2008). "Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients". The Journal of Thoracic and Cardiovascular Surgery. 136 (4): 884–93. doi:10.1016/j.jtcvs.2007.12.062. PMID 18954626.
  4. ^ Mathew JP, Shernan SK, White WD, Fitch JC, Chen JC, Bell L, Newman MF (October 2004). "Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery". Stroke. 35 (10): 2335–9. doi:10.1161/01.STR.0000141938.00524.83. PMID 15331798.
  5. ^ Mitchell S (2 January 2007). "Analysis: Alexion's pexelizumab fails". United Press International.
Zdroj:https://en.wikipedia.org?pojem=Pexelizumab
>Text je dostupný pod licencí Creative Commons Uveďte autora – Zachovejte licenci, případně za dalších podmínek. Podrobnosti naleznete na stránce Podmínky užití.

čítajte viac o Pexelizumab


čítajte viac na tomto odkaze: Pexelizumab



Hladanie1.

Monoclonal antibody
File:Engineered monoclonal antibodies.svg
Single-chain variable fragment
Monoclonal antibody#Production
Humanized
Mouse
Antigen
Complement component 5
Anatomical Therapeutic Chemical Classification System
Regulation of therapeutic goods
CAS Registry Number
ChemSpider
Unique Ingredient Identifier
KEGG
Wikipedia:WikiProject Chemicals/Chembox validation
Pharmaceutical drug
Coronary artery bypass grafting
Angioplasty
Cardiac surgery
Single chain variable fragment
Monoclonal antibody
Complement component 5
Complement system
ClinicalTrials.gov
ClinicalTrials.gov
Doi (identifier)
PMID (identifier)
Doi (identifier)
PMID (identifier)
Template:Immunosuppressants
Template talk:Immunosuppressants
Special:EditPage/Template:Immunosuppressants
Immunosuppressive drug
Immunosuppression
ATC code L04
Antimetabolite
Purine synthesis inhibitor
Azathioprine
Mycophenolic acid
Dihydroorotate dehydrogenase
Leflunomide
Teriflunomide
Antifolate
Methotrexate
Macrolide
Interleukin 2
FKBP
Cyclophilin
Calcineurin
Ciclosporin
Pimecrolimus
Tacrolimus
Voclosporin
Abetimus
Gusperimus
Immunomodulatory imide drug
Lenalidomide
Pomalidomide
Thalidomide
PDE4 inhibitor
Apremilast
Interleukin 1 receptor antagonist
Anakinra
MTOR
Everolimus
Ridaforolimus
Sirolimus
Temsirolimus
Umirolimus
Zotarolimus
Antibody
Monoclonal antibody
Complement component 5
Eculizumab
TNF inhibitor
Adalimumab
Afelimomab
Certolizumab pegol
Golimumab
Infliximab
Nerelimomab
Interleukin
Anakinra
Basiliximab
Bimekizumab
Briakinumab
Brodalumab
Canakinumab
Daclizumab
Guselkumab
Ixekizumab
Olokizumab
Rilonacept
Risankizumab
Sarilumab
Satralizumab
Secukinumab
Siltuximab
Sirukumab
Spesolimab
Tildrakizumab
Tocilizumab
Ustekinumab
Interleukin 5
Mepolizumab
Immunoglobulin E
Omalizumab
Interferon
Faralimomab
Interleukin 6
Elsilimomab
Interleukin 12
Interleukin 23
Lebrikizumab
Ustekinumab
Interleukin 17
Secukinumab
CD3 (immunology)
Muromonab-CD3
Otelixizumab
Teplizumab
Visilizumab
CD4
Clenoliximab
Keliximab
Zanolimumab
CD11a
Efalizumab
CD18
Erlizumab
CD20
Obinutuzumab
Ocrelizumab
Pascolizumab
Rituximab
Ublituximab
CD23
Gomiliximab
Lumiliximab
CD40 (protein)
Teneliximab
Toralizumab
L-selectin
Aselizumab
CD80
Galiximab
Basigin
Gavilimomab
CD154
Frexalimab
Ruplizumab
Belimumab
Chloramphenicol acetyltransferase
Bertilimumab
Lerdelimumab
Metelimumab
Integrin
Natalizumab
Vedolizumab
Interleukin-6 receptor
Tocilizumab
Lymphocyte function-associated antigen 1
Odulimomab
IL-2 receptor
Basiliximab
Daclizumab
Inolimomab
T cell
Zolimomab aritox
Alemtuzumab
Anifrolumab
Atorolimumab
Cedelizumab
Emapalumab
Fontolizumab
Inebilizumab
Maslimomab
Morolimumab
Ofatumumab
Reslizumab
Rovelizumab
Siplizumab
Talizumab
Telimomab aritox
Teprotumumab
Vapaliximab
Vepalimomab
Polyclonal antibodies
Anti-thymocyte globulin
Anti-lymphocyte globulin
Fusion protein
CTLA-4
Abatacept
Belatacept
TNF inhibitor
Etanercept
Aflibercept
Alefacept
Rilonacept
Avacopan
Baricitinib
Bimekizumab
Blisibimod
Briakinumab
Brodalumab
Canakinumab
Crovalimab
Danicopan
Darvadstrocel
Deucravacitinib
Deuruxolitinib
Dimethyl fumarate
Diroximel fumarate
Efgartigimod alfa
Efgartigimod alfa/hyaluronidase
Etrasimod
Filgotinib
Fingolimod
Guselkumab
Iptacopan
Ixekizumab
Olokizumab
Ozanimod
Peficitinib
Pegcetacoplan
Pirfenidone
Ponesimod
Ravulizumab
Risankizumab
Ritlecitinib
Rozanolixizumab
Sarilumab
Satralizumab
Siltuximab
Siponimod
Sirukumab
Spesolimab
Sutimlimab
Tildrakizumab
Tofacitinib
Upadacitinib
Template:Monoclonals for immune system
Template talk:Monoclonals for immune system
Special:EditPage/Template:Monoclonals for immune system
Monoclonal antibodies
Immune system
Immune system
Immunosuppression
Abrilumab
Adalimumab
Anifrolumab
Atorolimumab
Avelumab
Belimumab
Bleselumab
Brodalumab
Camidanlumab tesirine
Carlumab
Cemiplimab
Dupilumab
Eldelumab
Emapalumab
Fresolimumab
Golimumab
Ianalumab
Lanadelumab
Lenzilumab
Lerdelimumab
Lirentelimab
Lirilumab
Mavrilimumab
Metelimumab
Morolimumab
Namilumab
Oleclumab
Oxelumab
Pamrevlumab
Placulumab
Relatlimab
Sarilumab
Sifalimumab
Tabalumab
Tezepelumab
Ulocuplumab
Varlilumab
Ipilimumab
Durvalumab
Nivolumab
Tremelimumab
Urelumab
Bertilimumab
Zanolimumab
Nivolumab/relatlimab
Afelimomab
Elsilimomab
Faralimomab
Gavilimomab
Inolimomab
Maslimomab
Nerelimomab
Odulimomab
Telimomab aritox
Vepalimomab
Zolimomab aritox
Chimeric antibody
Andecaliximab
Basiliximab
Clenoliximab
Galiximab
Gomiliximab
Infliximab
Keliximab
Lumiliximab
Priliximab
Teneliximab
Vapaliximab
Humanized antibody
Apolizumab
Aselizumab
Updating...x




Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok.
Podrobnejšie informácie nájdete na stránke Podmienky použitia.